J Periodontal Res:格列本脲抑制大鼠咬合创伤引起的骨吸收

2020-06-28 MedSci原创 MedSci原创

机械应力过大,例如创伤性咬合,会诱导IL-1β表达,并可能参与骨吸收。 NLRP3炎性小体与IL-1β的表达有关,但目前尚不清楚其抑制剂格列本脲是否能抑制大鼠的咬合创伤。

机械应力过大,例如创伤性咬合,会诱导IL-1β表达,并可能参与骨吸收。 NLRP3炎性小体与IL-1β的表达有关,但目前尚不清楚NLRP3炎性小体的抑制剂格列本脲是否能抑制大鼠的咬合创伤。本研究旨在检测大鼠咬合创伤模型中,格列本脲是否能够抑制咬合创伤引起的骨破坏。

使用7周龄的雄性SD大鼠。在咬合创伤组中,通过连接金属丝将上颌右侧第一磨牙的咬合面抬高,以对下颌右侧第一磨牙施加咬合创伤。在咬合创伤+格列本脲组中,从诱发咬合创伤起每隔24小时口服一次NLRP3抑制剂格列本脲。在5或10天后对大鼠实施安乐死,并收集上颌第一磨牙进行组织病理学研究。免疫组织化学检测IL-1β,NLRP3和RANKL的表达水平。

结果发现,在第5天,与对照组或咬合创伤+格列本脲组相比,咬合创伤组的骨吸收更明显,并且咬合创伤组中IL-1β,NLRP3和RANKL阳性的破骨细胞和细胞数量明显增加。

因此,格列本脲通过抑制咬合创伤缓解大鼠的骨吸收,提示NLRP3 /IL-1β通路可能与咬合创伤引起的骨吸收有关。

原文出处:

Yoichi Arita,Glyburide inhibits the bone resorption induced by traumatic occlusion in rats. Journal of periodontal research, 2020 June. Doi: 10.1111/jre.12731

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1728575, encodeId=ec711e28575b1, content=<a href='/topic/show?id=986913980dd' target=_blank style='color:#2F92EE;'>#PE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13980, encryptionId=986913980dd, topicName=PE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f06c33759375, createdName=feather89, createdTime=Fri Jul 03 03:50:09 CST 2020, time=2020-07-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1642217, encodeId=8ac8164221e45, content=<a href='/topic/show?id=85d439e9855' target=_blank style='color:#2F92EE;'>#咬合创伤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=39798, encryptionId=85d439e9855, topicName=咬合创伤)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b9b022877135, createdName=41514494@qq.com, createdTime=Sat May 08 05:50:09 CST 2021, time=2021-05-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1335306, encodeId=288a1335306b7, content=<a href='/topic/show?id=e7cc32022c7' target=_blank style='color:#2F92EE;'>#创伤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32022, encryptionId=e7cc32022c7, topicName=创伤)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=aa5a2500103, createdName=ms920641618706883, createdTime=Tue Jun 30 02:50:09 CST 2020, time=2020-06-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1532616, encodeId=6403153261684, content=<a href='/topic/show?id=75991016300c' target=_blank style='color:#2F92EE;'>#骨吸收#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=101630, encryptionId=75991016300c, topicName=骨吸收)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=74d112366079, createdName=徐岩, createdTime=Tue Jun 30 02:50:09 CST 2020, time=2020-06-30, status=1, ipAttribution=)]
    2020-07-03 feather89
  2. [GetPortalCommentsPageByObjectIdResponse(id=1728575, encodeId=ec711e28575b1, content=<a href='/topic/show?id=986913980dd' target=_blank style='color:#2F92EE;'>#PE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13980, encryptionId=986913980dd, topicName=PE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f06c33759375, createdName=feather89, createdTime=Fri Jul 03 03:50:09 CST 2020, time=2020-07-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1642217, encodeId=8ac8164221e45, content=<a href='/topic/show?id=85d439e9855' target=_blank style='color:#2F92EE;'>#咬合创伤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=39798, encryptionId=85d439e9855, topicName=咬合创伤)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b9b022877135, createdName=41514494@qq.com, createdTime=Sat May 08 05:50:09 CST 2021, time=2021-05-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1335306, encodeId=288a1335306b7, content=<a href='/topic/show?id=e7cc32022c7' target=_blank style='color:#2F92EE;'>#创伤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32022, encryptionId=e7cc32022c7, topicName=创伤)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=aa5a2500103, createdName=ms920641618706883, createdTime=Tue Jun 30 02:50:09 CST 2020, time=2020-06-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1532616, encodeId=6403153261684, content=<a href='/topic/show?id=75991016300c' target=_blank style='color:#2F92EE;'>#骨吸收#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=101630, encryptionId=75991016300c, topicName=骨吸收)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=74d112366079, createdName=徐岩, createdTime=Tue Jun 30 02:50:09 CST 2020, time=2020-06-30, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1728575, encodeId=ec711e28575b1, content=<a href='/topic/show?id=986913980dd' target=_blank style='color:#2F92EE;'>#PE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13980, encryptionId=986913980dd, topicName=PE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f06c33759375, createdName=feather89, createdTime=Fri Jul 03 03:50:09 CST 2020, time=2020-07-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1642217, encodeId=8ac8164221e45, content=<a href='/topic/show?id=85d439e9855' target=_blank style='color:#2F92EE;'>#咬合创伤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=39798, encryptionId=85d439e9855, topicName=咬合创伤)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b9b022877135, createdName=41514494@qq.com, createdTime=Sat May 08 05:50:09 CST 2021, time=2021-05-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1335306, encodeId=288a1335306b7, content=<a href='/topic/show?id=e7cc32022c7' target=_blank style='color:#2F92EE;'>#创伤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32022, encryptionId=e7cc32022c7, topicName=创伤)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=aa5a2500103, createdName=ms920641618706883, createdTime=Tue Jun 30 02:50:09 CST 2020, time=2020-06-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1532616, encodeId=6403153261684, content=<a href='/topic/show?id=75991016300c' target=_blank style='color:#2F92EE;'>#骨吸收#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=101630, encryptionId=75991016300c, topicName=骨吸收)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=74d112366079, createdName=徐岩, createdTime=Tue Jun 30 02:50:09 CST 2020, time=2020-06-30, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1728575, encodeId=ec711e28575b1, content=<a href='/topic/show?id=986913980dd' target=_blank style='color:#2F92EE;'>#PE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13980, encryptionId=986913980dd, topicName=PE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f06c33759375, createdName=feather89, createdTime=Fri Jul 03 03:50:09 CST 2020, time=2020-07-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1642217, encodeId=8ac8164221e45, content=<a href='/topic/show?id=85d439e9855' target=_blank style='color:#2F92EE;'>#咬合创伤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=39798, encryptionId=85d439e9855, topicName=咬合创伤)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b9b022877135, createdName=41514494@qq.com, createdTime=Sat May 08 05:50:09 CST 2021, time=2021-05-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1335306, encodeId=288a1335306b7, content=<a href='/topic/show?id=e7cc32022c7' target=_blank style='color:#2F92EE;'>#创伤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32022, encryptionId=e7cc32022c7, topicName=创伤)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=aa5a2500103, createdName=ms920641618706883, createdTime=Tue Jun 30 02:50:09 CST 2020, time=2020-06-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1532616, encodeId=6403153261684, content=<a href='/topic/show?id=75991016300c' target=_blank style='color:#2F92EE;'>#骨吸收#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=101630, encryptionId=75991016300c, topicName=骨吸收)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=74d112366079, createdName=徐岩, createdTime=Tue Jun 30 02:50:09 CST 2020, time=2020-06-30, status=1, ipAttribution=)]
    2020-06-30 徐岩

相关资讯

JAMA:妊娠期糖尿病新生儿围产期并发症的预防——格列本脲VS胰岛素

研究认为,格列本脲和胰岛素对妊娠期糖尿病新生儿围产期并发症的预防效果差异不显著,胰岛素仍是妊娠期糖尿病的首选治疗药物

J Dent Res:磺酰脲类药物可用于治疗牙周炎

白细胞介素-1β(IL-1β)是一种由单核细胞/巨噬细胞产生的炎症细胞因子,与牙周病密切相关。在细菌感染中NLRP3炎症体通过亲IL-1β处理和细胞凋亡参与IL-1&be

Lancet Neurol:格列本脲能减轻梗死患者的脑水肿吗?(GAMES-RP)

卒中的临床前模型表明,静脉使用格列本脲可减轻脑水肿、改善生存率。我们对大面积半球梗死患者进行了研究,旨在评估静脉使用格列本脲能否安全的减轻脑水肿、降低去骨瓣减压的需要、改善患者的临床结果。 在这项双盲、随机、安慰剂对照的2期临床试验中,我们纳入了诊断前循环大面积半球梗死10小时内的患者(18-80岁),基线弥散加权MRI图像显示病变体积82–300 cm3。将患者按1:1随机分为安慰剂组或静

静脉用格列本脲治疗严重卒中有效

     2013年国际卒中大会(ISC)上公布的一项小型研究表明,含有一种普通的糖尿病药物格列本脲(Glyburide)的配方,可以大幅度降低严重卒中患者的死亡率。   GAMES(格列本脲在恶性脑水肿和卒中的优越性研究)为一开放标签研究,该研究只纳入了10名平均年龄为51岁的严重卒中患者,磁共振(MRI)显示脑梗死体积≥82m,这些卒中患者发生脑水肿的风险非常高且预后差,死亡率

Obstet Gynecol:格列本脲能够在母胎间转运

Rachelle A等人进行了一项回顾性观察性研究,以探究使用格列本脲治疗妊娠期糖尿病GDM时,通过胎盘转运至胎儿的格列本脲含量有多少。研究者们记录了GDM孕妇服用格列本脲的剂量和最后一次用药时间,当娩出胎儿后,立即抽取孕产妇血液和脐静脉血,运用高效液相色谱检测样本中格列本脲浓度,其最低可检测至0.25 ng/mL。最新研究成果发表在近期《Obstet Gynecol